The NIHR Health Protection Research Unit (HPRU) in Healthcare Associated Infections and Antimicrobial Resistance (AMR) is a partnership between Public Health England (PHE) and the University of Oxford in collaboration with University of Leeds, Animal and Plant Health Agency and European Bioinformatics Institute.
National Institute for Health Research (NIHR) has provided funding to establish 14 Health Protection Research Units (HPRU) to address key public health threats. The HPRUs are partnerships between Universities and Public Health England forming multi-disciplinary centres of excellence with a focus on collaborations and knowledge sharing.
HPRU in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University is led by Professor Sarah Walker and our PHE lead is Dr Susan Hopkins.
The HPRU in Healthcare Associated Infections and AMR vision is to find better ways to manage and prevent threats from antimicrobial resistance and healthcare-associated infections, by detecting them faster, working out who needs protecting most and how this can be done.
It consists of 4 broad Research Themes:
NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance
We want to create opportunities for individuals to interact, engage and contribute to our research to: Improve its quality and relevance: Ensure our research questions align with the wider public’s priorities: Disseminate findings to everyone who may find them relevant, useful or interesting: Inspire adults and children and promote careers in research and Science, Technology, Engineering, and Mathematics
Our strategy for knowledge mobilisation/policy-maker engagement is based on PHE leaders being best-placed to ensure HPRU studies directly inform PHE needs and results are disseminated beyond academia, including into PHE guidance/outputs
Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis
Sasson SC. et al, (2021), Gastroenterology, 161, 1229 - 1244.e9
Inborn errors of IL-6 family cytokine responses
Chen Y-H. et al, (2021), Current Opinion in Immunology, 72, 135 - 145
Renaming COPD exacerbations: the UK respiratory nursing perspective.
Mwasuku C. et al, (2021), BMC Pulm Med, 21
Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial.
Young BC. et al, (2021), Lancet (London, England)
21 September 2021
The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.
20 September 2021
‘Finding Our Way – An NHS Tribute Garden’ is a celebration of the incredible efforts of the thousands of people who fought – and are still fighting - the COVID-19 pandemic on our behalf. Designed by Naomi Ferrett-Cohen and presented by Oxford University Hospitals NHS Foundation Trust and Oxford University.
31 August 2021
The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks at his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.